Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ALOGLIPTIN

ALOGLIPTIN BENZOATE

Standard Dose
6.25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ALOGLIPTIN is listed in Drugs@FDA under application 210002 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN BENZOATE Form and strength TABLET;ORAL - 6.25MG Sponsor INDOCO REMEDIES Submission history Latest submission status date: 2019-12-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALOGLIPTIN is listed in Drugs@FDA under application 210002 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ALOGLIPTIN BENZOATE Form and strength TABLET;ORAL - 6.25MG Sponsor INDOCO REMEDIES Submission history Latest submission status date: 2019-12-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ALOGLIPTIN (ALOGLIPTIN BENZOATE) | Drug Monograph | MedicHelpline